Engineering the AAV capsid to evade immune responses

Current Opinion in Biotechnology
Christopher BarnesDavid Schaffer

Abstract

Gene therapy is progressively emerging as a promising and powerful therapeutic modality, and adeno-associated virus (AAV) is a major delivery vehicle for such therapies. Among the most significant challenges that limit AAV's utility, however, is the immune response it elicits. Antibodies elicited by prior exposure to natural virus or vector can bind to an AAV vector, preventing it from entering the cell. Furthermore, even if AAV manages to infect a target cell, these cells can then be attenuated by lymphocytes. Improvements in our understanding of how the immune system responds to AAV have guided engineering of the capsid to reduce those responses, yielding capsid variants that are much stealthier and more effective. This review summarizes recent advances in understanding the immune response to AAV as well as highlights engineering methods that enhance AAV's potential as a gene therapy vector.

Citations

Aug 8, 2019·Physiology·Courtney S YoungMelissa J Spencer
Nov 5, 2019·Wiley Interdisciplinary Reviews. RNA·Carl R ShotwellJ Andrew Berglund
Aug 25, 2020·The CRISPR Journal·Lavina Sierra TayPrashant Mali
Dec 25, 2019·Proceedings of the National Academy of Sciences of the United States of America·Yasmine El-Shamayleh, Gregory D Horwitz
Jul 19, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Joel M Gottesfeld
Jan 16, 2020·Biomedicines·Andrei A DeviatkinAlexander N Lukashev
Jul 28, 2019·Human Gene Therapy·Nerea ZabaletaGloria Gonzalez-Aseguinolaza
Sep 2, 2020·International Journal of Molecular Sciences·Andrés Felipe LealAngela Johana Espejo-Mojica
Oct 7, 2020·Nature Reviews. Drug Discovery·Navneet Matharu, Nadav Ahituv
Jan 28, 2021·Cancer Cell International·Xin XuXiaochun Zhang
Oct 20, 2020·Trends in Molecular Medicine·Bijay P DhungelJohn E J Rasko
Mar 27, 2021·Molecular Therapy. Methods & Clinical Development·Yuan MengYing Liu
May 29, 2021·RSC Medicinal Chemistry·Lewis L BrayshawChristopher Herring
Aug 10, 2021·Journal of Parkinson's Disease·Tomas Björklund, Marcus Davidsson
Oct 8, 2021·Clinical Obstetrics and Gynecology·Marisa E Schwab, Tippi C MacKenzie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Related Papers

European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V
Christian SchönStylianos Michalakis
Frontiers in Immunology
Roberto Calcedo, James M Wilson
Molecular Therapy : the Journal of the American Society of Gene Therapy
Roland W Herzog
© 2022 Meta ULC. All rights reserved